FDA report accuses Able Labs of fraudulent testing

The FDA says that Able Laboratories fraudulently altered quality tests to hide its failures from regulators. And an FDA report posted on Able's website says that senior management at Able failed to ensure that its products were safe. Changes to lab tests were done by "cutting and pasting" computer records by supervisors and lab workers in the lead-up to a recall of all its products last May. Able produced about 30 generic drugs up until it halted manufacturing operations. Able President Robert Mauro resigned a week ago.

- read this report from USA Today

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.